Shots:
- The P-III CASPIAN trial evaluates Imfinzi + CT or Imfinzi + CT + tremelimumab vs CT alone in 805 patients with ES-SCLC in 200+ centers across 23 countries, including the US, EU, South America, Asia & Middle East
- The results showed OS benefits & sustained efficacy after a median follow-up of ≥3yrs. with a 29% reduction in risk of death; m-OS (12.9 vs 10.5mos.), well-tolerated safety profile consistent with the known profiles of the therapy, patients experienced a serious AEs (32.5% vs 36.5%)
- In an exploratory analysis, patients were alive @3yrs. (17.6% vs 5.8%) & survival benefits were consistent across all subgroups. The therapy is also being evaluated in the P-III ADRIATIC trial for SCLC
Click here to read full press release/ article | Ref: Businesswire | Image: New Europe
The post AstraZeneca Presents the Updated Results of Imfinzi (durvalumab) in P-III CASPIAN Trial for the Treatment of Extensive-Stage Small Cell Lung Cancer at ESMO 2021 first appeared on PharmaShots.
